Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.71 |
| ▸ | CBFB | Q13951 | 1/20 | 0.63 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 8/20 | 0.54 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4182314 | 0.99 | TRPV1 (0.70) | TRPV1CBFBDGAT1KCNH2NPBWR1 | |
| Sulfuric Acid SCHEMBL4179926 | 0.94 | TRPV1 (0.64) | TRPV1CBFBDGAT1KCNH2NPBWR1 | |
| Phosphoric Acid SCHEMBL4183555 | 0.94 | TRPV1 (0.64) | TRPV1CBFBDGAT1KCNH2NPBWR1 | |
| SCHEMBL4182013 | 0.93 | TRPV1 (0.73) | TRPV1CBFBDGAT1KCNH2NPBWR1 | |
| SCHEMBL4185904 | 0.92 | TRPV1 (0.62) | TRPV1CBFBDGAT1KCNH2NPBWR1 | |
| SCHEMBL4179856 | 0.90 | TRPV1 (0.72) | TRPV1CBFBDGAT1KCNH2NPBWR1 | |
| SCHEMBL4189081 | 0.89 | TRPV1 (0.58) | TRPV1CBFBDGAT1KCNH2NPBWR1 | |
| SCHEMBL4189162 | 0.88 | TRPV1 (0.61) | TRPV1CBFBDGAT1KCNH2METAP2 | |
| SCHEMBL4193128 | 0.88 | CBFB (0.61) | TRPV1CBFBDGAT1KCNH2NPBWR1 | |
| Dwp05195 SCHEMBL904647 | 0.88 | TRPV1 (0.61) | TRPV1CBFBDGAT1KCNH2NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621915-B1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAE WOONG PHARMA (KR) | 2016-04-20 | — | — | EP | claimed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | claimed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | claimed |
| EP-1861387-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DAE WOONG PHARMA (KR) | 2014-04-16 | — | — | EP | claimed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | claimed |
| EP-2621915-B1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAE WOONG PHARMA (KR) | 2016-04-20 | — | — | EP | disclosed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | disclosed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | disclosed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | disclosed |
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-09-05 | — | — | US | disclosed |
| EP-2621915-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | Daewoong Pharmaceutical Co., Ltd (KR) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044043-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-04-05 | — | — | WO | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| EP-1861387-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006080821-A1 | NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | TRPV1, TRPA1, BDKRB2 | TRPV1 1/4885CBFB 1891/4885DGAT1 2290/4885 |
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | BRD1, BRD4, VAT1 | TRPV1 21/4885CBFB 3959/4885DGAT1 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.